



DISCLOSURE MATERIALS

Certified B Corporations must complete a Disclosure Questionnaire to identify potentially sensitive issues related to the company (e.g. historical fines, sanctions, material litigation, or sensitive industry practices).

This component does not affect the company's score on the B Impact Assessment. If the company answers affirmatively to any items in the Disclosure Questionnaire and B Lab deems them to be material, the company must:

- 1) Be transparent about the disclosure issues identified on the company's public B Impact Report
- 2) Describe how the company has addressed this issue.
- 3) Demonstrate that management systems are in place to avoid similar issues from arising in the future.

In all cases, the Standards Advisory council reserves the right to refuse certification if the company is ultimately deemed not to uphold the spirit of the community.

In addition to the voluntary indication of sensitive issues in the Disclosure Questionnaire, companies pursuing Certification also are subject to background checks by B Lab staff. Background checks include a review of public records, news sources, and search engines for company names, brands, executives/founders, and other relevant topics.

Sensitive issues identified through background checks may or may not be within the scope of questions in the Disclosure Questionnaire, but undergo the same review process and are subject to the same possible review by the Standards Advisory Council, including ineligibility for B Corp Certification, required remediation, or disclosure.

This document contains a copy of the company's completed Disclosure Questionnaire and related disclosure documentation provided by the company.



DISCLOSURE QUESTIONNAIRE

Company Name: Provepharm Life Solutions
Date Submitted: 07/06/2023

Industries & Products	Yes	No
Please indicate if the company is involved in production of or trade in any the following. Select Yes for all options that apply.		
Animal Products or Services	√	
Biodiversity Impacts		√
Chemicals	√	
Company Explanation Of Disclosure Item Flags		√
Disclosure Alcohol		√
Disclosure Firearms Weapons		√
Disclosure Mining		√
Disclosure Pornography		√
Disclosure Tobacco		√
Energy and Emissions Intensive Industries	√	
Fossil fuels		√
Gambling		√
Genetically Modified Organisms		√
Illegal Products or Subject to Phase Out		√
Industries at Risk of Human Rights Violations		√
Monoculture Agriculture		√
Nuclear Power or Hazardous Materials		√
Payday, Short Term, or High Interest Lending		√
Water Intensive Industries	√	
Tax Advisory Services		√

Supply Chain Disclosures	Yes	No
Please indicate if any of the following statements are true regarding your company's significant suppliers.		
Business in Conflict Zones		√
Child or Forced Labor		√
Negative Environmental Impact		√
Negative Social Impact		√
Other		√

Outcomes & Penalties	True	False
Please indicate if the company has had any formal complaint to a regulatory agency or been assessed any fine or sanction in the past five years for any of the following practices or policies. Check all that apply.		
Anti-Competitive Behavior		√
Breaches of Confidential Information		√
Bribery, Fraud, or Corruption		√
Company Explanation Of Disclosure Item Flags		√
Company has filed for bankruptcy		√
Consumer Protection		√
Financial Reporting, Taxes, Investments, or Loans		√
Hazardous Discharges Into Air/Land/Water (Past 5 Yrs)		√
Labor Issues		√
Large Scale Land Conversion, Acquisition, or Relocation		√
Litigation or Arbitration		√
On-Site Fatality		√
Penalties Assessed For Environmental Issues		√
Political Contributions or International Affairs		√
Recalls		√
Significant Layoffs		√
Violation of Indigenous Peoples Rights		√
Other		√

Practices	True	False
Please indicate if the following statements are true regarding whether or not the company engages in the following practices. Check all that apply. If the statement is true, select "Yes." If false, select "No."		
Animal Testing		√
Company/Suppliers Employ Under Age 15 (Or Other ILO Minimum Age)		√
Company Explanation Of Disclosure Item Flags		√
Company prohibits freedom of association/collective bargaining		√
Company workers are prisoners		√
Conduct Business in Conflict Zones		√
Confirmation of Right to Work		√
Does not transparently report corporate financials to government		√
Employs Individuals on Zero-Hour Contracts		√
Facilities located in sensitive ecosystems		√
ID Cards Withheld or Penalties for Resignation		√
No formal Registration Under Domestic Regulations		√
No signed employment contracts for all workers		√
Overtime For Hourly Workers Is Compulsory		√
Payslips not provided to show wage calculation and deductions		√
Sale of Data		√
Tax Reduction Through Corporate Shells		√
Workers cannot leave site during non-working hours		√
Workers not Provided Clean Drinking Water or Toilets		√
Workers paid below minimum wage		√
Workers Under Bond		√
Other		√



B Corp Certification - Disclosure Questionnaire Documentation

PROVIDED BY:

Provepharm Life Solutions

UPDATED AS OF:

07/06/2023

DISCLOSURE QUESTIONNAIRE CATEGORY	Environmentally Intensive Industries
TOPIC	Chemical Intensive Industries
SUMMARY OF ISSUE	<p>Provepharm is an independent French Pharmaceutical, with expertise in fine chemistry. As a company in the pharmaceutical industry, Provepharm Life Solutions operates in an industry in which chemical use is a material environmental issue.</p> <p>The company offers pharmacopoeial grade methylene blue for use in human and animal health applications and some of the input materials used during elaboration of products are CMRs.</p>
SIZE/SCOPE OF ISSUE (e.g. \$ financial implication, # of individuals affected)	<p>75% of the company's revenue is derived from the sale of the company's most chemically intensive product, Methylene Blue. The remaining 25% of the company's revenue is derived from the sale of other products that contain chemical inputs.</p>
IMPACT ON STAKEHOLDERS	<p>As a chemical-intensive industry, the company's production process poses risks to the environment such as pollution of air, land, and water, as well as potential human health risks to those exposed to harmful chemicals.</p> <p>The company uses chemicals as raw material to elaborate its pharmaceutical products so there are environmental risks in the case of spills, such as land and water pollution, as well as potential human health risks to those exposed to harmful chemicals without personal protective equipment throughout the production of the products or its handling by customers.</p> <p>Provepharm has not suffered any incidents and/or fines related to the environment. Provepharm suffered an accident involving an employee during the use of chemical products in 2022 (projection of product during handling).</p>
IMPLEMENTED MGT PRACTICES	<p>Provepharm fulfills the regulations in force and requirements related to the pharmaceutical sector. At each start of the production process, Provepharm conducts a risk analysis of the products and processes used in order to assess the reduction or replacement of the product(s) as well as the implementation of all the associated safety measures. The company operates a safety management system that includes processes, protections and controls aimed at ensuring the safety of employees and respect for the environment. All products are monitored using chemical management software (Quarks) allowing access to safety data sheets. All of the products used in the company's production or R&D are recovered in drums to be reprocessed by a chemical waste reprocessing company.</p> <p>The company does not measure the chemical intensity of its products nor does it conduct an assessment of how it compares to others in the industry in terms of chemical use and how these impacts are managed.</p>
MANAGEMENT COMMENTS	<p>The company follows the regulations in force and the requirements related to the pharmaceutical sector.</p>



B Corp Certification - Disclosure Questionnaire Documentation

PROVIDED BY:

Provepharm Life Solutions

UPDATED AS OF:

07/06/2023

DISCLOSURE QUESTIONNAIRE CATEGORY	Animal Testing
TOPIC	Company is required to undergo mandatory animal testing by law.
SUMMARY OF ISSUE	Provepharm Life Solutions is a pharmaceutical company that produces medicines that are required to be tested on animals under by law in the markets where they operate. The company subcontracts a third party facility to conduct the tests.
SIZE/SCOPE OF ISSUE (e.g. \$ financial implication, # of individuals affected)	<p>Around 22% of the company products undergo animal testing.</p> <p>The company has nine marketed products, two of which require animal testing:</p> <ul style="list-style-type: none"> Methylene Blue (which corresponds to 75% of the company's annual revenue). The test was carried out once, in 2011, at health authorities' request and conducted on dogs. The test does not need to be repeated. For this, two different studies have been performed on dogs. (1) The DRF to determine the dose to administer during the 4-weeks toxicity study. During this study, 4 dogs have been tested. And (2), a 4-weeks toxicity study. During this study, 30 dogs were tested. Indigo Carmine (which represents 0.6% of Provepharm Life Solutions' annual revenue). Test carried out in 2020 on 3 rabbits. The test does not need to be repeated.
IMPACT ON STAKEHOLDERS	Animal testing and experimentation are widely used to develop new medical products and to test the safety of other products. Many of these experiments can cause pain to the animals involved or reduce their quality of life in other ways.
IMPLEMENTED MGT PRACTICES	<ul style="list-style-type: none"> Clinical studies are limited to the maximum and only carried out at the request of the authorities. Animal tests are performed only when necessary, Both animal testings conducted were in compliance with Animal Health regulations, Most of the studies are fed by bibliography because the company mainly works on known products for which it redefines the purity requirements of the active ingredients to maximize their therapeutic potential or to explore new indications, For the studies requested and subcontracted, the study protocol is submitted to an ethics committee of the subcontracting company, The ethical committee reviews all study plans, in order to ensure that: animal use is carefully considered and fully justified; all possibilities for reduction, refinement and replacement have been evaluated; every effort is made to achieve a high standard of animal welfare. The company does not have an animal testing policy.



B Corp Certification - Disclosure Questionnaire Documentation

PROVIDED BY:

Provepharm Life Solutions

UPDATED AS OF:

07/06/2023

DISCLOSURE QUESTIONNAIRE CATEGORY	Environmentally Intensive Industries
TOPIC	Water Intensive Industries
SUMMARY OF ISSUE	Provepharm Life Solutions is a company that operates in the Pharmaceutical industry which has been recognized as water-intensive due to its manufacturing and cleaning processes.
SIZE/SCOPE OF ISSUE (e.g. \$ financial implication, # of individuals affected)	<p>The company stated that Methylene Blue is its best-selling and most water-intensive product. Provepharm Life Solutions has performed an internal calculation of this product's water consumption: The production of one batch of methylene blue represents ~9 m3 of water. About 30 kg are needed to cover the company's global needs, i.e. 3 batches and 27 m3 of water consumed per year.</p> <p>Methylene Blue represented 75.5% of the company's turnover in 2022.</p> <p>The water used in the manufacture of our products comes from the city water network which is then purified for pharmaceutical use.</p>
IMPACT ON STAKEHOLDERS	<p>As a water-intensive industry, the production of medicines poses risks such as water stress or depletion of local water sources if water use is not appropriately managed.</p> <p>The company's laboratory is located in Marseille, in the south of France, and produces small quantities of products mainly for research and development and the improvement of its industrial processes.</p> <p>The company's contractors, the main producers its products, are based in the Paris region, an area not subject to water stress according to the Ministry of Ecology (see Report section).</p>
IMPLEMENTED MGT PRACTICES	<ul style="list-style-type: none"> • Provepharm Life Solutions is currently working on better measuring its water consumption and working on the reuse of clean water for other uses, • The company has not taken any specific water use reduction targets at this time.
REPORT	<p>Drought in France Ministries Ecology Energy Territories:</p> <p>https://www.ecologie.gouv.fr/secheresse-economiser-leau</p>



B Corp Certification - Disclosure Questionnaire Documentation

PROVIDED BY:

Provepharm Life Solutions

UPDATED AS OF:

07/06/2023

DISCLOSURE QUESTIONNAIRE CATEGORY	Environmentally Intensive Industries
TOPIC	Energy and Emissions Intensive Industry
SUMMARY OF ISSUE	As a company operating in the pharmaceutical industry, Provepharm Life Solutions operates in an industry in which energy and carbon emissions is a material environmental issue. 39% of the company's emissions can be attributed to the distribution of its products to over 30 countries.
SIZE/SCOPE OF ISSUE (e.g. \$ financial implication, # of individuals affected)	75% of the company's revenue is derived from sales of the Methylene Blue product, the company's most energy intensive product. The product requires 498 tCO ₂ e, with an emission factor of 14857 kgCO ₂ e per kg of manufactured product.
IMPACT ON STAKEHOLDERS	<p>The construction industry is a major contributor to global carbon emissions.</p> <p>Provepharm source of energy on its production site in Marseille is exclusively electric.</p>
IMPLEMENTED MGT PRACTICES	<p>The company is committed to the French Agency for Ecological Transition (ADEME) ACT program allowing the company to identify its areas of progress, reduction targets and actions to be taken. Provepharm Life Solutions is currently in the Vision stage of this 5 step program (Assessment, Challenges/Opportunities, Vision, New Strategy and Action Plan) in which the company will define its reduction targets aligned with the Paris agreements. Targets are to be defined in February 2023. The company's forecasted target is a 28% reduction in Scope 1 emissions and 55% of scope 3 emissions by 2023, based on 2021 baseline emissions.</p> <p>The company does not currently carry out a comparative study to others in the industry nor implements best practices in relation to energy consumption and emissions.</p>